OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
Last trade$3.56
Day change-$0.04 (-1.11%)
Day range$3.51 – $3.68
Volume311,524
Market cap$249M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$248.57M
Price / earnings
—
Price / book
0.78×
Price / sales
2.21×
EV / sales
0.78×
EV / EBITDA
-2.22×
Profitability
Earnings per share
-$0.71
Return on assets
-13.63%
Return on equity
-15.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.88×
Quick ratio
7.68×
Cash ratio
6.39×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$48.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OSUR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$30.64M
$27.93M
$26.76M
$27.09M
$31.24M
$29.93M
$37.45M
$39.92M
Cost of revenue
$17.32M
$16.12M
$15.8M
$15.31M
$18.08M
$17.63M
$23.88M
$22.85M
Gross profit
$13.32M
$11.8M
$10.97M
$11.77M
$13.16M
$12.3M
$13.57M
$17.07M
Selling, general and administrative
$21.03M
$21.33M
$16.4M
$17.38M
$19.05M
$20.96M
$19.9M
$17.45M
Research and development
$9.44M
$13.65M
$11.42M
$10.11M
$11.4M
$9.6M
$6.09M
$5.62M
Total operating expenses
$7.9M
$35.07M
$30.8M
$27.86M
$31.19M
$31.04M
$25.98M
$23.07M
Operating income
$5.42M
-$23.27M
-$19.84M
-$16.09M
-$18.03M
-$18.74M
-$12.42M
-$6M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$6.3M
-$21.72M
-$18.43M
-$13.29M
-$17.69M
-$15.97M
-$9.51M
-$3.22M
Income taxes
$55K
-$432K
$210K
$47K
$2M
-$456K
$758K
$678K
Net income
$6.25M
-$22.38M
-$19.29M
-$13.71M
-$19.69M
-$16.04M
-$10.79M
-$4.51M
Net income attributable to common shareholders
$6.25M
-$22.38M
-$19.29M
-$13.71M
-$19.69M
-$16.04M
-$10.79M
-$4.51M
EBITDA
$7.87M
-$21.01M
-$12.86M
-$13.71M
-$15.46M
-$15.97M
-$9.92M
-$3.43M
Basic earnings per share
$0.09
-$0.32
-$0.27
-$0.19
-$0.26
-$0.21
-$0.14
-$0.06
Diluted earnings per share
$0.09
-$0.32
-$0.27
-$0.19
-$0.26
-$0.21
-$0.14
-$0.06
Recent news
Company coverage with links to the original publishers.
Prestige Consumer Healthcare reported Q2 earnings of $1.13 per share, beating consensus estimates of $1.06, with revenues of $336.31 million exceeding expectations by 2.31%. Despite the earnings beat, the stock has underperformed the market by 13.6% year-to-date. The company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
OraSure Technologies has joined the World Coalition on Sickle Cell Disease, an international public-private partnership aimed at strengthening global response to sickle cell disease. As a member, OraSure will contribute its diagnostics expertise in point-of-care testing to help advance early diagnosis, screening, and linkage to care, particularly in resource-limited health systems.
OraSure Technologies has joined the World Coalition on Sickle Cell Disease, an international public-private partnership aimed at improving global response to sickle cell disease. As a member, OraSure will contribute its diagnostic expertise in decentralized and point-of-care testing to support early diagnosis, screening, and healthcare system readiness, particularly in resource-limited settings.
OraSure Technologies has joined the World Coalition on Sickle Cell Disease, a public-private international partnership aimed at strengthening the global fight against sickle cell disease. As a member, OraSure will contribute diagnostic expertise to support early diagnosis, screening, and improved healthcare system capacity to address patient needs in various healthcare settings.
Following the WHO's declaration of a Public Health Emergency for the Bundibugyo virus Ebola outbreak on May 17, 2026, biodefense diagnostics companies are experiencing significant capital inflows. Co-Diagnostics is positioned as a strategic play due to its decentralized manufacturing network through joint ventures in India (CoSara) and Saudi Arabia (CoMira), which addresses national security demands for localized production. The company is advancing PCR assays for Ebola detection and has near-term catalysts including FDA 510(k) submission and India TB test commercialization in Q3 2026, though the stock's recent 200%+ surge on low float presents both opportunity and volatility.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.